Longitude Capital, a life science investment firm targeting mostly mid to late stage companies with about one quarter for early stage businesses, has made its first close for Longitude Venture Partners III, raising a total of $525 million, according to a company statement.
In a phone interview with Longitude Founder and Managing Director Marc Galletti, he said it would begin making investments from the newsest fund starting in the third quarter.
“We invest in exciting life science companies that can hit exciting milestones within three to five years of investment.”
Galletti highlighted some of the technologies in which it has demonstrated an interest, such as ophthalmology, mitrovalve repair, food allergies, oncology and neurostimulation.
It helped start Aimmune, a publicly traded biotech business developing a treatment for peanut allergies affecting children that’s in phase three development. It also invested in Twelve, a medical device company that developed a transcatheter mitrovalve replacement device that Medtronic acquired last year.
In April it invested in Kala Pharmaceuticals, a biotechnology company developing ophthalmology products such as a treatment for pain and inflammation following cataract surgery.
Photo: Flickr user Peasap